Claims
- 1. A method of treating an individual having an tumor comprising:
injecting an individual near a site of said infection or tumor with an effective amount of genetically modified professional antigen presenting cells, wherein said professional antigen presenting cells have been genetically modified to enhance expression of an immunostimulatory cytokine.
- 2. A method as in claim 1 wherein said professional antigen presenting cells are dendritic cells.
- 3. A method as in claim 2 wherein said dendritic cells have been genetically modified by transduction with a viral vector encoding said cytokine.
- 4. A method as in claim 3 wherein said viral vector is a retroviral vector.
- 5. A method as in claim 3 wherein said viral vector is selected from the group consisting of adenoviral vectors and adeno-associated viral vectors.
- 6. A method as in claim 4 wherein said dendritic cells have been genetically modified by centrifuging said professional antigen presenting cells with the supernatant of producer cells expressing said retroviral vector encoding said cytokine.
- 7. A method as in claim 2 wherein said dendritic cells are selected from the group consisting of CD34+-derived dendritic cells, bone marrow-derived dendritic cells, monocyte-derived dendritic cells, splenocyte derived dendritic cells, skin-derived dendritic cells, follicular dendritic cells, and germinal center dendritic cells.
- 8. A method as in claim 2 wherein said dendritic cells are CD34+-derived dendritic cells cultured in the presence of at least one factor selected from the group consisting of G-CSF, GM-CSF, TNF-α, IL-4, the Flt-3 ligand and the kit ligand.
- 9. A method as in claim 1 wherein said cytokine is selected from the group consisting of the interleukins (e.g., IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-8, IL-9, IL-10, IL-12, IL-18, IL-19, IL-20), the interferons (e.g., IFN-α, IFN-β, IFN-γ), tumor necrosis factor (TNF), transforming growth factor-β (TGF-β), granulocyte colony stimulating factors (G-CSF), macrophage colony stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), the Flt-3 ligand and the kit ligand.
- 10. A method as in claim 1 wherein said individual has a cancer selected from the group consisting of melanomas, hepatomas, adenocarcinomas, basal cell cancers, oral cancers, nasopharyngeal cancers, laryngeal cancers, bladder cancers, head and neck cancers, renal cell cancers, pancreatic cancers, pulmonary cancers, cervical cancers, ovarian cancers, esophageal cancers, gastric cancers, prostate cancers, testicular cancers, and breast cancers.
- 11. A method of treating an individual having an infection comprising:
injecting an individual near a site of said infection or tumor with an effective amount of genetically modified professional antigen presenting cells professional antigen presenting cells, wherein said professional antigen presenting cells have been genetically modified to enhance expression of an immunostimulatory cytokine.
- 12. A method as in claim 11 wherein said professional antigen presenting cells are dendritic cells.
- 13. A method as in claim 12 wherein said dendritic cells have been genetically modified by transduction with a viral vector encoding said cytokine.
- 14. A method as in claim 13 wherein said viral vector is a retroviral vector.
- 15. A method as in claim 13 wherein said viral vector is selected from the group consisting of adenoviral vectors and adeno-associated viral vectors.
- 16. A method as in claim 14 wherein said dendritic cells have been genetically modified by centrifuging said professional antigen presenting cells with the supernatant of producer cells expressing said retroviral vector encoding said cytokine.
- 17. A method as in claim 12 wherein said dendritic cells are selected from the group consisting of CD34+-derived dendritic cells, bone marrow-derived dendritic cells, monocyte-derived dendritic cells, splenocyte derived dendritic cells, skin-derived dendritic cells, follicular dendritic cells, and germinal center dendritic cells.
- 18. A method as in claim 12 wherein said dendritic cells are CD34+-derived dendritic cells cultured in the presence of at least one factor selected from the group consisting of G-CSF, GM-CSF, TNF-α, IL-4, the Flt-3 ligand and the kit ligand.
- 19. A method as in claim 11 wherein said cytokine is selected from the group consisting of the interleukins (e.g., IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-8, IL-9, IL-10, IL-12, IL-18, IL-19, IL-20), the interferons (e.g., IFN-α, IFN-β, IFN-γ), tumor necrosis factor (TNF), transforming growth factor-β (TGF-β), granulocyte colony stimulating factors (G-CSF), macrophage colony stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), the Flt-3 ligand and the kit ligand.
GOVERNMENT RIGHTS IN THE INVENTION
[0001] This work was supported in part by Grant Number POI CA59371 from the National Cancer Institute of the National Institutes of Health. The government has certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60100468 |
Sep 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09395836 |
Sep 1999 |
US |
Child |
10213939 |
Aug 2002 |
US |